IRIS
RIMINI, MARGHERITA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.689
NA - Nord America 2.116
AS - Asia 2.071
SA - Sud America 460
AF - Africa 48
OC - Oceania 7
Totale 7.391
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.022
RU - Federazione Russa 1.609
SG - Singapore 781
CN - Cina 632
BR - Brasile 379
IT - Italia 295
RO - Romania 263
HK - Hong Kong 230
VN - Vietnam 210
FR - Francia 118
DE - Germania 101
SE - Svezia 72
GB - Regno Unito 69
IN - India 48
CA - Canada 47
MX - Messico 35
AR - Argentina 32
BD - Bangladesh 31
JP - Giappone 31
NL - Olanda 30
FI - Finlandia 27
AT - Austria 25
PL - Polonia 24
ZA - Sudafrica 22
ES - Italia 19
IQ - Iraq 14
TR - Turchia 14
ID - Indonesia 13
CL - Cile 9
CO - Colombia 9
LT - Lituania 9
MA - Marocco 9
EC - Ecuador 8
IE - Irlanda 8
AU - Australia 7
SA - Arabia Saudita 7
VE - Venezuela 7
EG - Egitto 6
PK - Pakistan 6
AE - Emirati Arabi Uniti 5
BE - Belgio 5
NP - Nepal 5
PH - Filippine 5
UY - Uruguay 5
UZ - Uzbekistan 5
IR - Iran 4
PY - Paraguay 4
TW - Taiwan 4
UA - Ucraina 4
AZ - Azerbaigian 3
BO - Bolivia 3
LB - Libano 3
SI - Slovenia 3
TT - Trinidad e Tobago 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
DZ - Algeria 2
HN - Honduras 2
IL - Israele 2
KG - Kirghizistan 2
KR - Corea 2
KW - Kuwait 2
KZ - Kazakistan 2
MD - Moldavia 2
MY - Malesia 2
OM - Oman 2
SR - Suriname 2
AL - Albania 1
BB - Barbados 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
CM - Camerun 1
CY - Cipro 1
GA - Gabon 1
GT - Guatemala 1
GY - Guiana 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
LK - Sri Lanka 1
MV - Maldive 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SV - El Salvador 1
TH - Thailandia 1
TN - Tunisia 1
Totale 7.391
Salva come PNG Salva come JPEG
Città #
Dallas 944
Singapore 479
Moscow 327
Ashburn 227
Hong Kong 224
Beijing 148
San Jose 137
New York 90
Ho Chi Minh City 83
Shanghai 78
Lauterbourg 77
Hefei 64
Los Angeles 63
Milan 59
Hanoi 41
Orem 36
Santa Clara 34
Rome 33
São Paulo 32
Munich 28
Tokyo 28
Boardman 27
Montreal 21
Nuremberg 21
Poplar 20
Warsaw 20
Guangzhou 19
Lawrence 19
London 19
Princeton 19
Stockholm 19
Council Bluffs 18
Cesano Boscone 17
Denver 17
Helsinki 17
Mexico City 16
Frankfurt am Main 15
Vienna 15
Brooklyn 14
Chicago 14
Da Nang 14
Manchester 14
Rio de Janeiro 14
Toronto 14
Chennai 13
Johannesburg 13
Romagnano Sesia 13
Houston 12
Phoenix 12
Biên Hòa 11
Atlanta 10
Boston 10
Naples 10
Lappeenranta 9
Dhaka 8
Haiphong 8
Monza 8
Shenzhen 8
Amsterdam 7
Bologna 7
Dublin 7
Porto Alegre 7
Ankara 6
Bacoli 6
Belo Horizonte 6
Brasília 6
Falkenstein 6
Mumbai 6
Philadelphia 6
San Francisco 6
Washington 6
Buenos Aires 5
Montevideo 5
New Delhi 5
Querétaro 5
Seattle 5
Tashkent 5
Tianjin 5
Assago 4
Brisbane 4
Brussels 4
Cairo 4
Cape Town 4
Catania 4
Changsha 4
Columbus 4
Contagem 4
Duque de Caxias 4
Erbil 4
Guarulhos 4
Honolulu 4
Joinville 4
Londrina 4
Niterói 4
Pelotas 4
Pisa 4
Quinta Normal 4
Quito 4
Riyadh 4
Salvador 4
Totale 3.985
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 424
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 417
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 343
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 115
Combined hepatocellular-cholangiocarcinoma: morpho-molecular updates and considerations 115
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 112
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 111
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 110
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 109
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 108
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 105
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 103
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 103
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 102
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 101
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 101
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 97
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 96
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 95
Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 94
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 93
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 91
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 91
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 91
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 90
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 89
Angiogenesis in biliary tract cancer: targeting and therapeutic potential 86
Cholangiocarcinoma: new perspectives for new horizons 86
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 85
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 83
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 83
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 81
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 80
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 78
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 78
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 77
Correction: Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 77
The oncologic burden of residual disease in incidental gallbladder cancer: An elastic net regression model to profile high-risk features 75
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 72
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 72
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 70
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 70
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 70
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 69
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 68
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 67
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 66
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 66
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index 66
Clinical implications of malnutrition in the management of patients with pancreatic cancer: Introducing the concept of the nutritional oncology board 65
The prognostic value of the new combined hemo-eosinophil inflammation index (Hei index): A multicenter analysis of anal cancer patients treated with concurrent chemo-radiation 65
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 63
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 62
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma 62
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib 62
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 61
Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis (Targeted Oncology, (2021), 16, 3, (401-410), 10.1007/s11523-021-00797-3) 61
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study 59
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 59
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 57
Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report 57
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 57
Child Pugh and ALBI grade: past, present or future? 57
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients 57
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis 57
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 57
The Prognostic Role of Baseline Eosinophils in HPV-Related Cancers: a Multi-institutional Analysis of Anal SCC and OPC Patients Treated with Radical CT-RT 56
The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center 53
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 53
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study 53
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 52
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation 52
Lenvatinib as a therapy for unresectable hepatocellular carcinoma 52
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 52
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 51
Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 50
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma 50
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 49
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases 48
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 48
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 45
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 44
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 44
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib 43
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 42
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 42
Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development 42
Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors? 41
Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib 40
Radial and Longitudinal Margins in Surgery of Perihilar Cholangiocarcinoma: When R1 Definition Is Associated with Different Prognosis 38
External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study 37
Surgery for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: milestone changes in the last two decades potentially affecting current guidelines 37
Correction to: Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 30
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies 29
Il trattamento del carcinoma squamocellulare cutaneo localmente avanzato e metastatico 28
Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study 28
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 22
Letter Re: Reflections on the MAGIC-D Prognostic Model in Advanced Biliary Tract Cancer 10
null 7
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 1
Totale 7.618
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.440
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.440
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202218 0 0 0 1 0 0 2 12 2 0 0 1
2022/2023118 42 20 4 1 1 22 7 7 8 2 1 3
2023/2024224 12 3 31 18 13 50 3 15 0 5 24 50
2024/20251.228 92 27 18 13 38 91 384 140 122 79 62 162
2025/20266.025 385 685 814 737 527 225 426 468 1.543 215 0 0
Totale 7.618